ERBB2 and adenocarcinoma: Significant improvements in patient OS (12.5 vs. 8.4 months; P = 0.0097) and response rate (51.3% vs. 14.3%) compared with standard therapy were observed, and a survival benefit was also reported in patients with G/GEJ adenocarcinoma with low HER2 expression, with myelosuppression and interstitial lung disease being the major adverse events [24].